PMID- 24198204
OWN - NLM
STAT- MEDLINE
DCOM- 20140717
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 30
IP  - 4
DP  - 2013 Dec
TI  - The hypoxia-inducible factor-1 regulates the microRNA185 expression through 
      binding to hypoxia response elements sequence 2.
PG  - 756
LID - 10.1007/s12032-013-0756-8 [doi]
AB  - This study aimed to investigate the interaction and regulatory mechanism of 
      microRNA185 (miR185) and hypoxia-inducible factor-1 (HIF-1) in pancreatic cancer. 
      The significance of miR185 on the clinicopathologic characteristics and prognosis 
      was further explored. qRT-PCR and immunohistochemistry examined miR185 and HIF-1 
      expression of tumor tissues. Western blot analyzed HIF-1 protein expression. We 
      regulated HIF-1 via transfection to observe the impact of HIF-1 on miR185 
      expression. ChIP sequencing and dual luciferase identified binding sites of HIF-1 
      and miR185. MiR185 expression was significantly higher in pancreatic tumors. 
      MiR185 closely associated with tumor size, pTNM stage, lymph node, and perneural 
      invasion. After hypoxic culture, both HIF-1 and miR185 expression of MiaPaCa2 and 
      AsPc1 cells increased significantly. Up- or down-regulating HIF-1 expression via 
      transfection leads to synchronous alteration of miR185. In ChIP sequencing, only 
      the HRE2 (-938 bp) was significantly brighter under hypoxia among four hypoxia 
      response elements' (HREs) sequence of miR185 promoter. After pGL3-miR185 and 
      HIF-1 over-expressing plasmids co-transfect the MiaPaCa2 cells, its relative 
      expression of bioluminescence increased. MiR185 expression was significantly 
      higher in tumor tissues and closely associated with the clinical features of 
      pancreatic cancer. Expression of HIF-1 in pancreatic cancer cells increased in 
      hypoxia. HIF-1 may bind to HRE2 of miR185 and initiate its transcription.
FAU - Song, Zhenguo
AU  - Song Z
AD  - Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin, China.
FAU - Ren, He
AU  - Ren H
FAU - Gao, Song
AU  - Gao S
FAU - Zhao, Tiansuo
AU  - Zhao T
FAU - Wang, Xiuchao
AU  - Wang X
FAU - Zhang, Shengjie
AU  - Zhang S
FAU - Zhao, Xiao
AU  - Zhao X
FAU - Jia, Lingling
AU  - Jia L
FAU - Sun, Junwei
AU  - Sun J
FAU - Hao, Jihui
AU  - Hao J
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20131107
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (HIGD1A protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (MIRN185 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
RIN - Med Oncol. 2015 Feb;32(2):436. PMID: 25572808
MH  - Cell Hypoxia/genetics
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins
MH  - MicroRNAs/*genetics/metabolism
MH  - Mitochondrial Proteins
MH  - Neoplasm Proteins/*genetics/metabolism
MH  - Pancreatic Neoplasms/chemistry/*genetics/metabolism
MH  - Response Elements
MH  - Transcription Factors/genetics/metabolism
EDAT- 2013/11/08 06:00
MHDA- 2014/07/18 06:00
CRDT- 2013/11/08 06:00
PHST- 2013/08/27 00:00 [received]
PHST- 2013/10/24 00:00 [accepted]
PHST- 2013/11/08 06:00 [entrez]
PHST- 2013/11/08 06:00 [pubmed]
PHST- 2014/07/18 06:00 [medline]
AID - 10.1007/s12032-013-0756-8 [doi]
PST - ppublish
SO  - Med Oncol. 2013 Dec;30(4):756. doi: 10.1007/s12032-013-0756-8. Epub 2013 Nov 7.